Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas

References

• Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of SYK protein tyrosine kinase. J. Biochem.130, 177–186 (2001).
   PubMed Web of Science ®Google Scholar
• Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature378, 303–306 (1995).
   PubMed Web of Science ®Google Scholar
• Moon K, Post CB, Durden L et al. Molecular basis for a direct interaction between the SYK protein tyrosine kinase and phosphoinositide 3-kinase. J. Biol. Chem.280, 1543–1551 (2005).
   PubMedGoogle Scholar
• Kurosaki T, Johnson SA, Pao L, Sada K, Yamamura H, Cambier JC. Role of the SYK autophosphorylation site and SH2 domains in B cell antigen receptor signaling. J. Exp. Med.182, 1815–1823 (1995).
   PubMed Web of Science ®Google Scholar
• Beitz LO, Fruman A, Kurosaki T, Cantley LC, Scharenberg AM. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J. Biol. Chem.274, 32662–32666 (1999).
   PubMedGoogle Scholar
• Okada T, Maeda A, Iwamatsu A, Gotoh K, Kurosaki T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity13, 817–827 (2000).
   PubMed Web of Science ®Google Scholar
• Buhl AM, Cambier JC. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor mediated activation of Bruton’s tyrosine kinase. J. Immunol.162, 4438–4446 (1999).
   PubMedGoogle Scholar
• Ingham RJ, Santos L, Dang-Lawson M et al. The Gabl locking protein links the B cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway andto the SHP2 tyrosine phosphatase. J. Biol. Chem.276, 12257–12265 (2001).
   PubMedGoogle Scholar
• DeFranco AL. Transmembrane signaling by antigen receptors of B and T lymphocytes. Curr. Opin. Cell Biol.7, 163–175 (1995).
   PubMedGoogle Scholar
• Hsueh RC, Scheuermann RH. Tyrosine kinase activation in the decision between growth, differentiation, and death responses initiated from the B cell antigen receptor. Adv. Immunol.75, 283–316 (2000).
   PubMed Web of Science ®Google Scholar
• Koretzky GA, Abtahian F, Silverman MA. SLP76 and SLP65: complex regulation of signaling in lymphocytes and beyond. Nat. Rev. Immunol.6, 67–78 (2006).
   PubMed Web of Science ®Google Scholar
• Law CL, Sidorenko SP, Chandran KA et al. Molecular cloning of human Syk. A B cell protein tyrosine kinase associated with the surface immunoglobulin M–B cell receptor complex. J. Biol. Chem.269, 12310–12319 (1994).
   PubMedGoogle Scholar
• Leseux L, Hamdi SM, Al Saati T et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood108, 4156–4162 (2006).
   PubMed Web of Science ®Google Scholar
• Ding J, Takano T, Gao S et al. Syk is required for the activation of Akt survival pathway in B cells exposed to oxidative stress. J. Biol. Chem.275, 30873–30877 (2000).
   PubMed Web of Science ®Google Scholar
• Qin S, Minami Y, Hibi M, Kurosaki T, Yamamura H. Syk-dependent and -independent signaling cascades in B cells elicited by osmotic and oxidative stress. J. Biol. Chem.272, 2098–2103 (1997).
   PubMed Web of Science ®Google Scholar
• Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc. Natl Acad. Sci. USA107, 2902–2907 (2010).
   PubMedGoogle Scholar
• Peters JD, Furlong MT, Asai DJ, Harrison ML, Geahlen RL. Syk, activated by crosslinking the B cell antigen receptor, localizes to the cytosol where it interacts with and phosphorylates alpha tubulin on tyrosine. J. Biol. Chem.271, 4755–4762 (1996).
   PubMedGoogle Scholar
• Sulimenka V, Draberova E, Sulimenka T et al. Regulation of microtubule formation in activated mast cells by complexes of g tubulin with Fyn and Syk kinases. J. Immunol.176, 7243–7253 (2006).
   PubMedGoogle Scholar
• Faruki S, Geahlen RL, Asai DJ. Syk-dependent phosphorylation of microtubules in activated B lymphocytes. J. Cell Sci.113, 2557–2565 (2000).
   PubMedGoogle Scholar
• Lebouvier T, Scales TM, Hanger DP et al. The microtubule-associated protein Tau is phosphorylated by Syk. Biochim. Biophys. Acta1783, 188–192 (2008).
   PubMedGoogle Scholar
• Nogales E, Wolf SG, Khan IA, Luduena RF, Downing KH. Structure of tubulin at 6.5Å and location of the taxol binding site. Nature375, 424–427 (1995).
   PubMed Web of Science ®Google Scholar
• Zyss D, Montcourrier P, Vidal B et al. The SYK tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression. Cancer Res.65, 10872–10880 (2005).
   PubMedGoogle Scholar
• He J, Takano T, Gao S et al. Syk is required for p38 activation and G2/M arrest in B-cells exposed to oxidative stress. Antioxid. Redox Signal.4, 509–515 (2002).
   PubMedGoogle Scholar
• Wossning T, Herzog S, Kohler F et al. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J. Exp. Med.13, 2829–2840 (2006).
   Google Scholar
• Baudot AD, Jeandel PY, Mouska X et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression. Oncogene28, 3261–3273 (2009).
   PubMed Web of Science ®Google Scholar
• Buchner M, Fuchs S, Prinz G et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res.69, 5424–5432 (2009).
   PubMed Web of Science ®Google Scholar
• Chen L, Monti S, Juszczynski P et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large cell lymphoma. Blood111, 2230–2237 (2008).
   PubMed Web of Science ®Google Scholar
• Gobessi S, Laurenti L, Longo PG et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B-cells. Leukemia 23, 686–697 (2009).
   Google Scholar
• Quiroga MP, Balakrishnan K, Kurtova AV et al. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood114, 1029–1037 (2009).
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Kwee I, Taborelli M et al. Genomic and expression profiling identifies the B cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Hematol.132, 303–316 (2006).
   PubMed Web of Science ®Google Scholar
• Young RM, Hardy IR, Clarke RL et al. Mouse models of non-Hodgkin’s lymphoma reveal Syk as an important therapeutic target. Blood113, 2508–2516 (2009).
   PubMed Web of Science ®Google Scholar
• Uckun FM, Ek RO, Jan ST, Chen CL, Qazi S. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic. Br. J. Hematol.149, 508–517 (2010).
   PubMed Web of Science ®Google Scholar
• Yu K, Ganesan K, Tan LK et al. A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet.4, e1000129 (2008).
   PubMed Web of Science ®Google Scholar
• Weston VJ, Austen B, Wei W et al. Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF κB survival pathway signaling. Blood104, 1465–1473 (2004).
   PubMedGoogle Scholar
• Marston E, Weston V, Jesson J et al. Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response. Blood113, 117–126 (2009).
   PubMed Web of Science ®Google Scholar
• Crazzolara R, Bradstock KF, Bendall LJ. RAD001 (everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy5, 727–728 (2009).
   PubMed Web of Science ®Google Scholar
• Uckun FM, Dibirdik I, Qazi S. Augmentation of the anti-leukemic potency of total body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK). Radiat. Res. (2010) (In press).
   PubMedGoogle Scholar
• Uckun FM, Ozer Z, Qazi S, Tuel-Ahlgren L, Mao C. Polo-like kinase 1 (PLK1) as a molecular target to overcome Syk-mediated resistance of B-lineage acute lymphoblastic leukemia cells to oxidative stress. Br. J. Hematol.148, 714–725 (2010).
   PubMedGoogle Scholar
• Ruzza P, Biondi B, Calderan A. Therapeutic prospect of Syk inhibitors. Expert Opin. Ther. Patents19(10), 1361–1376 (2009).
   PubMedGoogle Scholar
• Hirabayashi A, Mukaiyama H, Kobayashi H et al. A novel Syk family kinase inhibitor: design, synthesis, and structure–activity relationship of 1,2,4-triazole[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives. Biorg. Med. Chem.16, 7347–7357 (2008).
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetham J et al. Inhibition of SYK with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood115, 2578–2585 (2010).
   PubMedGoogle Scholar
• Atwell S, Adams JM, Badger J et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem.279, 55827–55832 (2004).
   PubMed Web of Science ®Google Scholar
• Villasenor AG, Kondru R, Ho H et al. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystollagraphic analysis of three inhibitor complexes. Chem. Biol. Drug Des.73, 466–470 (2009).
   PubMed Web of Science ®Google Scholar
• Marsilje TH, Milkiewicz KL, Hangauer DG. The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 1: hydroxynaphthalene derivatives. Bioorg. Med. Chem. Lett.10, 477–481 (2000).
   PubMed Web of Science ®Google Scholar
• Ye G, Tiwari R, Parang K. Development of Src tyrosine kinase substrate binding site inhibitors. Curr. Opin. Investig. Drugs9, 605–613 (2008).
   PubMedGoogle Scholar
• Matsuda M, Park JG, Wang DC et al. Abrogation of the Fc γ receptor IIA-mediated phagocytic signal by stem-loop Syk antisense oligonucleotides. Mol. Biol. Cell7, 1095–1106 (1996).
   PubMedGoogle Scholar
• Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov.7, 771–782 (2008).
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res.14, 1310–1316 (2008).
   PubMed Web of Science ®Google Scholar
• Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther.5, 1909–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng WWK, Das D, Suresh M, Allen TM. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim. Biophys. Acta1768, 21–29 (2007).
   PubMed Web of Science ®Google Scholar
• Cheng WWK, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab’ fragments and single chain Fv. J. Control. Release126, 50–58 (2008).
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Ansari A, Xu J et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res.32, e149 (2004).
   PubMed Web of Science ®Google Scholar
• Zhukovsky E, Horton H, Lawrence CE et al. XmAb5574: in vitro and in vivo efficacy of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia and its effect on B cells in non-human primates. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 3078).
   Google Scholar
• Kugler M, Stein C, Schwenkert M et al. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng. Des. Sel.22, 135–147 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang J, Tang Y, Shen H, Qian B. Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8. J. Huazhong Univ. Sci. Technol.29, 273–280 (2009).
   PubMed Web of Science ®Google Scholar
• Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin. Hematol.46, 52–63 (2009).
   PubMed Web of Science ®Google Scholar
• Trigg ME, Sather H, Reaman GH et al. Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Leuk. Lymphoma49, 1142–1154 (2008).
   PubMed Web of Science ®Google Scholar
• Seibel NL, Steinherz PG, Sather HN et al. Early postinduction intensification therapy improves survival for children and adolescents with high risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood111, 2548–2555 (2008).
   PubMed Web of Science ®Google Scholar
• Gaynon PS. Childhood acute lymphoblastic leukemia and relapse. Br. J. Haematol.131, 579–587 (2005).
   PubMed Web of Science ®Google Scholar
• Gaynon PS, Harris RE, Altman AJ et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children’s Oncology Group Study CCG-1941. J. Clin. Oncol.24, 3150–3156 (2006).
   PubMed Web of Science ®Google Scholar
• Eapen M, Raetz E, Zhang MJ et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in second remission: a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood107, 4961–4967 (2006).
   PubMed Web of Science ®Google Scholar
• Malempati S, Gaynon PS, Sather H, La MK, Stork LC. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children’s Oncology Group study CCG-1952. J. Clin. Oncol.25, 5800–5807 (2007).
   PubMed Web of Science ®Google Scholar
• Roy A, Cargill A, Love S et al. Outcome after first relapse in childhood acute lymphoblastic leukemia – lessons from the United Kingdom R2 trial. Br. J. Hematol.130, 67–75 (2005).
   PubMed Web of Science ®Google Scholar
• Bailey LC, Lange BJ, Rheinhold SR, Bunin NJ. Bone marrow relapse in paediatric acute lymphoblastic leukemia. Lancet Oncol.9, 873–883 (2008).
   PubMed Web of Science ®Google Scholar
• Roy A, Cargill A, Love S et al. Outcome after first relapse in childhood acute lymphoblastic leukemia – lessons from the United Kingdom R2 trial. Br. J. Hematol.130, 67–75 (2005).
   PubMed Web of Science ®Google Scholar
• Uckun FM, Morar S, Qazi S. Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukemias. Br. J. Haematol.135, 500–508 (2006).
   PubMed Web of Science ®Google Scholar
• Uckun FM, Chandan-Langlie M, Jaszcz W, Obuz V, Waddick K, Song CW. Radiation damage repair capacity of primary clonogenic blasts in acute lymphoblastic leukemia. Cancer Res.53, 1431–1436 (1993).
   PubMed Web of Science ®Google Scholar
• Uckun FM, Jaszcz W, Chandan-Langlie M, Waddick KG, Gajl-Peczalska K, Song CW. Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. J. Clin. Invest.91, 1044–1051 (1993).
   PubMed Web of Science ®Google Scholar
• Hahn CK, Berchuk JE, Ross KN et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell16, 281–294 (2009).
   PubMed Web of Science ®Google Scholar
• Song Z, Lu P, Furman RR et al. Activities of SYK and PLCg2 predict apoptotic response of CLL cells to Src tyrosine kinase inhibitor dasatinib. Clin. Cancer Res.16, 587–599 (2010).
   PubMed Web of Science ®Google Scholar
• Dennehy KM, Ferwerda G, Faro-Trindade I et al. Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur. J. Immunol.38, 500–506 (2008).
   PubMed Web of Science ®Google Scholar
• Gevrey JC, Isaac BM, Cox D. SYK is required for monocyte/macrophage chemotaxis to CX3CL1 (Fracalkine). J. Immunol.175, 3737–3745 (2005).
   PubMedGoogle Scholar